The Liver Cancer Immune Microenvironment: Emerging Concepts for Myeloid Cell Profiling with Diagnostic and Therapeutic Implications-Reference-Cited by-同舟云学术

The Liver Cancer Immune Microenvironment: Emerging Concepts for Myeloid Cell Profiling with Diagnostic and Therapeutic Implications

Published:2023-02-28 Issue:5 Volume:15 Page:1522
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Arvanitakis Konstantinos¹²^ORCID,Mitroulis Ioannis³,Chatzigeorgiou Antonios⁴^ORCID,Elefsiniotis Ioannis⁵,Germanidis Georgios¹²^ORCID

Affiliation:

1. First Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece

2. Basic and Translational Research Unit (BTRU) of Special Unit for Biomedical Research and Education (BRESU), Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece

3. First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, Greece

4. Department of Physiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

5. University Department of Internal Medicine, General and Oncology Hospital of Kifisia Agioi Anargyroi, 14564 Athens, Greece

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide [...]

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

https://www.mdpi.com/2072-6694/15/5/1522/pdf

Reference27 articles.

1. Emerging immunotherapy for HCC: A guide for hepatologists;Foerster;Hepatology,2022

2. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma;Cheng;J. Hepatol.,2022

3. From NASH to HCC: Current concepts and future challenges;Anstee;Nat. Rev. Gastroenterol. Hepatol.,2019

4. NASH limits anti-tumour surveillance in immunotherapy-treated HCC;Pfister;Nature,2021

5. Muhammed, A., Fulgenzi, C.A.M., Dharmapuri, S., Pinter, M., Balcar, L., Scheiner, B., Marron, T.U., Jun, T., Saeed, A., and Hildebrand, H. (2021). The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. Cancers, 14.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RAD51 High-Expressed Hepatocellular Carcinomas are Associated With High Cell Proliferation;Journal of Surgical Research;2024-10

2. Shedding light on the role of LAG-3 in hepatocellular carcinoma: unraveling immunomodulatory pathways;Hepatoma Research;2024-04-26

3. New daphnane diterpenoidal 1,3,4-oxdiazole derivatives as potential anti-hepatoma agents: Synthesis, biological evaluation and molecular modeling studies;Bioorganic Chemistry;2024-04

4. γδ T Cells: A Game Changer in the Future of Hepatocellular Carcinoma Immunotherapy;International Journal of Molecular Sciences;2024-01-23

5. Reciprocal interactions between malignant cells and macrophages enhance cancer stemness and M2 polarization in HBV-associated hepatocellular carcinoma;Theranostics;2024